Virios Therapeutics (VIRI) Competitors $5.46 -0.25 (-4.29%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. CKPT, SNDL, TRDA, OLMA, BNTC, ARCT, HRTX, SEPN, FULC, and ATYRShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), Fulcrum Therapeutics (FULC), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Benitec Biopharma Arcturus Therapeutics Heron Therapeutics Septerna Fulcrum Therapeutics Atyr PHARMA Virios Therapeutics (NASDAQ:VIRI) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations. Which has higher earnings and valuation, VIRI or CKPT? Virios Therapeutics has higher earnings, but lower revenue than Checkpoint Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-20.24Checkpoint Therapeutics$41K8,539.84-$51.85M-$1.29-3.24 Does the media prefer VIRI or CKPT? In the previous week, Checkpoint Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Checkpoint Therapeutics and 0 mentions for Virios Therapeutics. Checkpoint Therapeutics' average media sentiment score of 0.56 beat Virios Therapeutics' score of 0.00 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Checkpoint Therapeutics Positive Which has more volatility & risk, VIRI or CKPT? Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Does the MarketBeat Community favor VIRI or CKPT? Checkpoint Therapeutics received 179 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Checkpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Do analysts recommend VIRI or CKPT? Virios Therapeutics presently has a consensus price target of $3.00, indicating a potential downside of 45.11%. Checkpoint Therapeutics has a consensus price target of $4.33, indicating a potential upside of 3.67%. Given Checkpoint Therapeutics' higher possible upside, analysts clearly believe Checkpoint Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders have more ownership in VIRI or CKPT? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is VIRI or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Checkpoint Therapeutics N/A N/A -659.07% SummaryCheckpoint Therapeutics beats Virios Therapeutics on 9 of the 15 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.25M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-20.248.9226.8219.71Price / SalesN/A252.24388.85117.28Price / CashN/A65.8538.2534.62Price / Book27.336.466.804.50Net Income-$5.30M$143.98M$3.23B$248.18M7 Day Performance12.68%2.03%1.53%0.20%1 Month Performance1.77%4.11%10.05%12.37%1 Year Performance2,584.18%-2.87%16.76%7.04% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$5.47-4.3%$3.00-45.1%+2,875.0%$105.25MN/A-20.245CKPTCheckpoint Therapeutics2.045 of 5 stars$4.16-0.2%$4.33+4.2%+110.1%$349.30M$41,000.00-2.2610News CoveragePositive NewsSNDLSNDL3.0665 of 5 stars$1.32+2.3%$3.63+174.6%-44.5%$346.86M$927.61M-4.26580Positive NewsTRDAEntrada Therapeutics2.9463 of 5 stars$8.82+5.3%$25.67+191.0%-51.0%$334.75M$172.22M5.55110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2647 of 5 stars$4.76+3.5%$27.67+481.2%-46.5%$325.40MN/A-2.1770BNTCBenitec Biopharma2.4208 of 5 stars$13.14-3.6%$24.71+88.1%+42.3%$319.64M$80,000.00-8.7020News CoverageAnalyst ForecastAnalyst RevisionARCTArcturus Therapeutics2.9265 of 5 stars$11.59+5.6%$59.20+410.8%-59.3%$314.33M$138.39M-5.22180HRTXHeron Therapeutics3.8615 of 5 stars$2.05-2.8%$5.50+168.3%-45.3%$312.76M$148.52M-11.39300Positive NewsSEPNSepterna2.0583 of 5 stars$6.98+4.3%$33.00+372.8%N/A$310.72M$1.08M0.00N/AEarnings ReportAnalyst RevisionFULCFulcrum Therapeutics0.7844 of 5 stars$5.68+5.8%$8.63+51.8%-18.2%$306.60M$80M-18.32100ATYRAtyr PHARMA2.8167 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553Analyst Forecast Related Companies and Tools Related Companies Checkpoint Therapeutics Alternatives SNDL Alternatives Entrada Therapeutics Alternatives Olema Pharmaceuticals Alternatives Benitec Biopharma Alternatives Arcturus Therapeutics Alternatives Heron Therapeutics Alternatives Septerna Alternatives Fulcrum Therapeutics Alternatives Atyr PHARMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIRI Stock Free VIRI Stock Alerts